generic times product news

MAY 01, 2007

Amoxicillin and Clavulanate Potassium for Oral Suspension USP

Marketed by: Ranbaxy Pharmaceuticals Inc, a wholly owned subsidiary of Ranbaxy Laboratories Ltd (Guragon, India)

Compared to: Augmentin ES-600 for Oral Suspension (GlaxoSmithKline)

Indication: January 31, 2007?Ranbaxy Pharmaceuticals announced that it received final approval from the FDA to market amoxicillin and clavulanate potassium for oral suspension USP, 600 mg/42.9 mg (base)/5 mL. The product is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis characterized by the following risk factors: antibiotic exposure for acute otitis media within the preceding 3 months and either of the following: age <2 years or day-care attendance.

Dosage Form: 600 mg/42.9 mg (base)/5 mL

For More Information:

Cabergoline Tablets

Marketed by: Teva Pharmaceuticals (North Wales, Pa)

Compared to: Dostinex (Pharmacia Italia S.p.A.)

Indication: March 7, 2007?Teva Pharmaceuticals announced the introduction and availability of Cabergoline Tablets. Cabergoline is a dopamine receptor agonist. The product is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. This product is AB-rated and bioequivalent to Dostinex Tablets. Cabergoline Tablets are available in unit-of-use bottle sizes of 8, in a dosage strength of 0.5 mg.

Dosage Form: Tablets: 0.5 mg

For More Information:

Cefadroxil Tablets

Marketed by: West-ward Pharmaceutical Corp (Eatontown, NJ)

Compared to: Duricef (Warner Chilcott)

Indication: April 13, 2007?West-ward Pharmaceutical Corp launched Cefadroxil 1-g tablets, a semisynthetic cephalosporin antibiotic intended for oral administration. The product is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in urinary tract infections caused by Escherichia coli, Proteus mirabilis, and Klebsiella species; skin and skin structure infections caused by staphylococci and/or streptococci; and pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.

Dosage Form: Tablets: 1 g

For More Information: 800-631-2174

Moexipril Hydrochloride and Hydrochlorothiazide Tablets

Marketed by: Teva Pharmaceuticals (North Wales, Pa)

Compared to: Uniretic Tablets (Warner-Lambert Co)

Indication: March 7, 2007?Teva Pharmaceuticals launched Moexipril Hydrochloride and Hydrochlorothiazide Tablets. The product is a combination of an angiotensin-converting enzyme inhibitor, moexipril hydrochloride, and a diuretic, hydrochlorothiazide. Moexipril Hydrochloride and Hydrochlorothiazide Tablets are indicated for the treatment of patients with hypertension. The recommended dosage range of moexipril is 7.5 to 30 mg daily, administered in a single dose or 2 divided doses 1 hour before meals, while hydrochlorothiazide is effective in a dosage of 12.5 to 50 mg daily.

Dosage Form: Tablets: 7.5 mg/12.5 mg, 15 mg/12.5 mg, 15 mg/25 mg

For More Information:


Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.